The global gene delivery technologies market size is accounted at USD 6.19 billion in 2025 and is forecasted to hit around USD 22.79 billion by 2034, representing a CAGR of 15.60% from 2025 to 2034. The North America market size was estimated at USD 2.25 billion in 2024 and is expanding at a CAGR of 15.58% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Gene Delivery Technologies Industry Impact
5.2. COVID-19 - Impact Assessment for the Industry
5.3. COVID-19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Gene Delivery Technologies Market, by Delivery System
8.1.1 Viral Gene Delivery Systems
8.1.1.1. Market Revenue and Forecast
8.1.2. Non-Viral Gene Delivery System
8.1.2.1. Market Revenue and Forecast
8.1.3. Combined Hybrid Delivery Systems
8.1.3.1. Market Revenue and Forecast
9.1. Gene Delivery Technologies Market, by Application
9.1.1. Gene therapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Cell therapy
9.1.2.1. Market Revenue and Forecast
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast
9.1.4. Research
9.1.4.1. Market Revenue and Forecast
10.1. Gene Delivery Technologies Market, by March
10.1.1. Ex Vivo
10.1.1.1. Market Revenue and Forecast
10.1.2. In Vivo
10.1.2.1. Market Revenue and Forecast
10.1.3. In Vitro
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Delivery System
11.1.2. Market Revenue and Forecast, by Application
11.1.3. Market Revenue and Forecast, by Method
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Delivery System
11.1.4.2. Market Revenue and Forecast, by Application
11.1.4.3. Market Revenue and Forecast, by Method
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Delivery System
11.1.5.2. Market Revenue and Forecast, by Application
11.1.5.3. Market Revenue and Forecast, by Method
11.2. Europe
11.2.1. Market Revenue and Forecast, by Delivery System
11.2.2. Market Revenue and Forecast, by Application
11.2.3. Market Revenue and Forecast, by Method
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Delivery System
11.2.4.2. Market Revenue and Forecast, by Application
11.2.4.3. Market Revenue and Forecast, by Method
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Delivery System
11.2.5.2. Market Revenue and Forecast, by Application
11.2.5.3. Market Revenue and Forecast, by Method
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Delivery System
11.2.6.2. Market Revenue and Forecast, by Application
11.2.6.3. Market Revenue and Forecast, by Method
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Delivery System
11.2.7.2. Market Revenue and Forecast, by Application
11.2.7.3. Market Revenue and Forecast, by Method
11.3. APAC
11.3.1. Market Revenue and Forecast, by Delivery System
11.3.2. Market Revenue and Forecast, by Application
11.3.3. Market Revenue and Forecast, by Method
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Delivery System
11.3.4.2. Market Revenue and Forecast, by Application
11.3.4.3. Market Revenue and Forecast, by Method
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Delivery System
11.3.5.2. Market Revenue and Forecast, by Application
11.3.5.3. Market Revenue and Forecast, by Method
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Delivery System
11.3.6.2. Market Revenue and Forecast, by Application
11.3.6.3. Market Revenue and Forecast, by Method
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Delivery System
11.3.7.2. Market Revenue and Forecast, by Application
11.3.7.3. Market Revenue and Forecast, by Method
11.4. MEA
11.4.1. Market Revenue and Forecast, by Delivery System
11.4.2. Market Revenue and Forecast, by Application
11.4.3. Market Revenue and Forecast, by Method
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Delivery System
11.4.4.2. Market Revenue and Forecast, by Application
11.4.4.3. Market Revenue and Forecast, by Method
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Delivery System
11.4.5.2. Market Revenue and Forecast, by Application
11.4.5.3. Market Revenue and Forecast, by Method
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Delivery System
11.4.6.2. Market Revenue and Forecast, by Application
11.4.6.3. Market Revenue and Forecast, by Method
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Delivery System
11.4.7.2. Market Revenue and Forecast, by Application
11.4.7.3. Market Revenue and Forecast, by Method
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Delivery System
11.5.2. Market Revenue and Forecast, by Application
11.5.3. Market Revenue and Forecast, by Method
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Delivery System
11.5.4.2. Market Revenue and Forecast, by Application
11.5.4.3. Market Revenue and Forecast, by Method
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Delivery System
11.5.5.2. Market Revenue and Forecast, by Application
11.5.5.3. Market Revenue and Forecast, by Method
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Becton, Dickinson and Company
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. F. Hoffmann-La Roche Ltd
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Thermo Fisher Scientific, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. QIAGEN
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Horizon Discovery Group Co.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. OriGene Technologies, Inc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. SignaGen Laboratories
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Bio-Rad Laboratories, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample